查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球 PICC（外周插入式中央靜脈導管）市場-2022-2029
市場調查報告書
商品編碼
1143404

全球 PICC（外周插入式中央靜脈導管）市場-2022-2029

Global Peripherally Inserted Central Catheter Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

PICC（外周插入中心靜脈導管）市場規模預計在預測期間（2022-2029 年）將以 5% 的複合年增長率增長。

PICC（外周插入中央靜脈導管）將一根細而柔軟的柔性管插入上臂靜脈，並將其引導（擰入）心臟右上方的一條大靜脈，稱為上腔靜脈。該靜脈輸液管允許靜脈內給藥並有助於採集血液進行測試。

市場動態

醫療保健專業人員使用 PICC 的趨勢不斷增長，這推動了市場的發展，因為 PICC 與其他導管相比具有優勢。由於慢性病增加導致住院人數增加，也增加了 PICC 的使用，推動了全球市場的增長。

醫療保健專業人員對 PICC 的偏好日益增加以及慢性病負擔的增加正在推動全球市場的增長。

醫療保健專業人員越來越喜歡 PICC 而非常規 IV 線，這推動了全球市場的增長。由於 PICC 線比常規 IV 更粗、更耐用，因此它們具有幾個優點，例如更長的長度和更深地穿透靜脈。通過使用 PICC 管路而不是常規 IV 管路，醫護人員可以將其放置更長時間（長達 3 個月，有時更長）並減少抽血所需的針刺數量。對於需要靜脈注射抗生素數週、靜脈營養、需要多次輸血的重症感染患者，也是一種非常有效的手段。此外，慢性病負擔的增加也在加速 PICC 的使用。例如，世衛組織的數據顯示，每年有 4100 萬人死於非傳染性疾病 (NCD)。預計到 2030 年將增加到 5200 萬，佔所有死亡人數的 75%（佔全球所有死亡人數的 74%），8 年內將有 1700 萬人死於非傳染性疾病，其中 86% 發生在低收入和中等收入國家。此外，全球非傳染性疾病聯盟估計，在 2011 年至 2030 年間，僅心血管疾病、呼吸系統疾病、糖尿病和癌症的影響將導致全球累計生產力損失 47 萬億美元。

並發症和缺乏熟練的專業人員正在阻礙全球外周插入中心靜脈導管市場的增長。

但是，並發症和相關風險正在限制全球市場的增長。例如，導管會引起感染、深靜脈血栓形成 (DVT)、血栓性靜脈炎和脫落等問題。此外，線路阻塞遲早會發生。嚴重的並發症和治療延誤會導致發病率惡化、痛苦增加，有時甚至是致命的後果。此外，缺乏訓練有素的專業人員正在阻礙全球市場的增長。例如，插管必須由經過專門培訓的專業人員進行，因為存在嚴重並發症的風險，例如氣胸、動脈穿刺、血胸、中風、心律失常和神經損傷。

COVID-19 影響分析

在 COVID-19 期間，ICU 入院人數激增，需要延長中心靜脈通路以進行藥物插入以及血液樣本採集和營養輸注。此外，由於 COVID-19 是一種 ARDS，我們能夠為需要機械通氣的患者增加俯臥位的氧氣輸送。上肢靜脈中的 PICC 是放置在俯臥位患者中難度最低且最可行的中心靜脈導管。因此，人保財險在COVID-19疫情期間銷量猛增，對疫情期間的市場產生了積極影響。

細分分析

預計在預測期內（2022-2029 年），電力注入 PICC 細分市場需求旺盛。

動力注入 PICC 細分市場主導著全球外周插入中心導管市場，預計在預測期內（2022-2029 年）將保持主導地位。 PICC 適用於重症監護病房，用作所有輸液的多用途中心靜脈管路，包括高流量輸液、血流動力學監測和放射檢查期間高壓注射造影劑（回顧性研究） .插入是 100% 成功的，並且不會造成重大風險，即使是在患有凝血病的患者中也是如此。此外，感染性和非感染性並發症的發生率極低，維修方便。應用包括高流量輸注、高壓注射和放射治療期間的血流動力學監測。

區域分析

預計北美將主導全球外周插入中心靜脈導管市場。

北美在全球市場中佔有最大份額，預計將在整個預測期內（2022-2029 年）佔據主導地位。市場份額大、醫院數量多、醫療成本高、老年人口不斷增長、癌症、糖尿病和心血管疾病等非傳染性疾病病例增加等主要市場參與者的存在，因為它在後台.例如，根據美國醫院協會 2022 年統計報告，根據 2020 年財務數據，美國 6,093 家醫院，共有 920,531 張床位，2020 年將有 33,356,853 人住院，投資額為 12138.81 億美元。知道其中涉及成本。根據醫療保險和醫療補助服務中心的數據，到 2020 年，全國醫療保健支出將增長 9.7%，達到 4.1 萬億美元，佔國內生產總值 (GDP) 的 19.7%。

此外，隨著人口老齡化，非傳染性疾病發病率的上升確保了北美在全球市場的主導地位。根據美國國家癌症研究所的數據，2020 年有 1,806,590 名癌症患者被診斷出，606,520 人報告死亡，美國癌症協會估計，2021 年將有超過 190 萬人患有癌症。估計有 608,570 人死亡。此外，根據 CDC 的數據，每 34 秒就有一人死於 CVS，到 2020 年 9 月，約有 620 萬人將出現心力衰竭，美國有超過 3700 萬成年人患有糖尿病，其中五分之一。是糖尿病。人口普查局的 2020 年人口估計顯示，超過 5500 萬美國人年齡在 65 歲及以上。

競爭格局

全球外周插入式中央靜脈導管市場的主要參與者是： AngioDynamics, Inc., Bard Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic plc, Vygon S.A., Cook Medical, Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Argon Medical Devices, Inc. ，Medical Component Inc，Thergenics Corporation。通過產品發布、併購、合作夥伴和聯盟等戰略，這些市場參與者正在為全球外周插入中心導管市場的增長做出貢獻。例如，2022 年 7 月 12 日，Medtronic宣布與 CathWorks 達成共同推廣協議，並宣布計劃收購它。此外，2022 年 3 月 8 日，Vygon 收購了秘魯經銷商 Macatt Medica。

Medtronic（Plc.

概述

Medtronic plc 是一家總部位於愛爾蘭的美國醫療設備製造商。Medtronic成立於 1949 年，總部位於美國明尼蘇達州明尼阿波利斯。美敦力經營四項業務：微創治療組、糖尿病組、恢復性治療組和心血管組。

產品組合

Medtronic 的外周插入中心靜脈導管產品組合包括 Chameleon PTA 球囊導管。

全球外周插入式中央靜脈導管市場報告提供對大約 40 多個市場數據表、45 多個圖表和估計 200 頁的訪問。成為。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 醫療保健醫師對 PICC 的偏好日益增加
      • 慢性病負擔加重
      • 市場策略
    • 約束因素
      • 缺乏熟練的專業人員
      • 相關並發症
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 動力注入
  • 常規

第 8 章按設計類型

  • 單腔
  • 雙腔
  • 多腔

第 9 章，最終用戶

  • 醫院
  • 門診手術中心 (ASC)
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • Medtronic, Plc
    • 公司簡介
    • 製作產品組合和描述
    • 主要亮點
    • 財務摘要
  • AngioDynamics, Inc.
  • Bard Inc.
  • Teleflex Incorporated
  • B Braun Melsungen AG
  • Vygon S.A
  • Cook Medical, Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Argon Medical Devices, Inc.
  • Medical Component Inc.
  • Theragenics Corporation（*未詳盡列出）

第 13 章數據M

簡介目錄
Product Code: DMMD61

Market Overview

Peripherally Inserted Central Catheter market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5% during the forecast period (2022-2029).

Peripherally Inserted Central Catheter (PICC) is a slim, soft, flexible tube inserted into a vein in the upper arm and guided (threaded) into a large vein above the right side of the heart called the superior vena cava. This intravenous line allows IV medication delivery and facilitates obtaining blood for laboratory testing.

Market Dynamics

The market is pushed by the increasing inclination by healthcare physicians for PICC because of the advantages offered by the PICC compared to other catheters. Also, the growing burden of chronic diseases leads to increased hospitalizations, thereby increasing the use of PICC and fueling the global market growth.

Healthcare physicians' increasing preference for PICC and the growing burden of chronic diseases propel global market growth.

Healthcare physicians' increasing preference for PICC over regular IV lines drives the global market growth. Because it offers a few advantages, such as a thicker and more durable PICC line than a regular IV, it's much more elongated and goes farther into the vein. Health care providers utilize a PICC line instead of a regular IV line because it can remain in place longer (up to 3 months and sometimes a bit more), decreasing the number of needle sticks a child requires for blood draws. Patients can get considerable amounts of fluids or medicines (like chemotherapy) that might not run via standard IVs; it can help someone with a serious infection so they can get IV antibiotics for a few weeks, helps those who need IV nutrition and is also very valuable in case of patients who will need numerous blood transfusions. Furthermore, the increasing burden of chronic diseases also accelerates using PICC. For instance, WHO data signifies that non-communicable diseases (NCDs) kill 41 million people yearly. They are being projected to escalate to 52 million, accounting for 75% of all deaths within just eight years by 2030, equivalent to 74% of all deaths globally; over 17 million people die from an NCD before age 70; 86% of these premature deaths occur in low- and middle-income countries. Furthermore, per the NCD Alliance at the global level, it is estimated that between 2011-2030, the toll of cardiovascular disease, respiratory disease, diabetes and cancer alone could result in a cumulative global loss in productivity of an estimated USD 47 trillion.

The complications and lack of skilled professionals hinder the growth of the global peripherally inserted central catheter market.

However, the complications and associated risks are restraining the global market growth. For instance, the catheters may cause difficulties such as infection, deep venous thrombosis (DVT), thrombophlebitis, and dislodgement. Furthermore, line blockage may occur sooner or later. Severe complications or delayed treatment can lead to increased morbidity, suffering, and occasionally, even a fatal outcome. Furthermore, the lack of trained professionals is hampering the global market growth. For instance, as the placement of these tubes bears a significant risk for serious complications, e.g., pneumothorax, arterial puncture, haemothorax, stroke, arrhythmias and nerve damage, thus must be performed by a specially trained professional.

COVID-19 Impact Analysis

During COVID-19, the ICU admissions were spiked, which required central venous access for longer to draw blood samples and insert medication along with nutritional IVs. Also, as COVID-19 is ARDS, the prone positioning of the patients helped to enhance oxygenation in patients who need a mechanical ventilator. The least challenging and most feasible central venous catheter to place in prone patients is a PICC in an upper extremity vein. Thus, there was a steep rise in PICC sales during the COVID-19 pandemic, which impacted the market positively during the pandemic period.

Segment Analysis

The power-injected PICC segment is predicted to have a high demand during the forecast period (2022-2029).

The power-injected PICC segment dominated the global peripherally inserted central catheters market and is predicted to dominate throughout the forecast period (2022-2029). Because of their advantages in intensive care units such as according to a retrospectively reviewed study, they can be utilized as multipurpose central lines for any infusion, including high-flow infusion, hemodynamic monitoring, and for high-pressure injection of contrast media during radiological processes. Their insertion is successful in 100% of cases and is not associated with substantial risks, even in patients with coagulation disorders. Their upkeep is associated with an extremely low rate of infective and non-infective complications. Applications include high-flow infusions, high-pressure injections and hemodynamic monitoring during radiological procedures.

Geographical Analysis

North America is predicted to command the global peripherally inserted central catheter market.

North America has the largest share in the global market and is expected to dominate throughout the forecast period (2022-2029). Since there is the presence of key market players holding the majority of market share, a large number of hospitals, high healthcare spending, a growing geriatric population, and rising cases of non-communicable diseases like cancer, diabetes, and cardiovascular diseases. For instance, the American Hospital Association statistics 2022 report, financial data from 2020 shows that 6,093 U.S. hospitals with 920,531 total staffed beds had 33,356,853 hospital admission in 2020, causing $1,213,881,001,000 expenses. In addition, according to the Centers for Medicare & Medicaid Services, in 2020, National Health Expenditure grew 9.7% to $4.1 trillion, accounting for 19.7% of Gross Domestic Product (GDP).

Moreover, the growing incidences of non-communicable diseases with the growing geriatric population ensure North America's dominance over the global market. According to National Cancer Institute, in 2020, there were 1,806,590 cancer cases diagnosed and 606,520 cancer deaths reported; American Cancer Society 2021 estimated that over 1.9 million were diagnosed and 608,570 died of cancer. Also, according to the CDC, one person dies every 34 seconds of CVS, and around 6.2 million had heart failure till September 2020; over 37 million U.S. adults with diabetes and 1 out of 5 of them don't know they have it. In addition, over 55 million Americans are 65 or older, per the estimate from the Census Bureau's 2020 population.

Competitive Landscape

The major global peripherally inserted central catheter market players are: AngioDynamics, Inc., Bard Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic plc, Vygon S.A, Cook Medical, Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Argon Medical Devices, Inc., Medical Component Inc., and Theragenics Corporation. Through strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, these market players contribute globally to the growth of the peripherally inserted central catheters market. For instance, in July 12, 2022, Medtronic announced a co-promotion agreement with CathWorks, with an acquisition plan. Also, in March 8, 2022, Vygon acquired Macatt Medica, a Peruvian distribution company.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The Medtronic, Plc product portfolio for peripherally inserted central catheters contains Chameleon PTA Balloon Catheter.

The global peripherally inserted central catheters market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Preference for PICC By Healthcare Physicians
      • 4.1.1.2. Growing Burden of Chronic Diseases
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Skilled Professional
      • 4.1.2.2. Associated Complication
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Power Injected
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Conventional

8. By Design Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type Segment
    • 8.1.2. Market Attractiveness Index, By Design Type Segment
  • 8.2. Single Lumen
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Double Lumen
  • 8.4. Multiple Lumen

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers (ASCs)
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Medtronic, Plc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AngioDynamics, Inc.
  • 12.3. Bard Inc.
  • 12.4. Teleflex Incorporated
  • 12.5. B Braun Melsungen AG
  • 12.6. Vygon S.A
  • 12.7. Cook Medical, Inc.
  • 12.8. Becton, Dickinson and Company
  • 12.9. Boston Scientific Corporation
  • 12.10. Argon Medical Devices, Inc.
  • 12.11. Medical Component Inc.
  • 12.12. Theragenics Corporation(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us